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Abstract
Background: Associations between BMI and DNA methylation of hypoxia-inducible factor 3-alpha (HIF3A) in both
blood cells and subcutaneous adipose tissue (SAT) have been reported. In this study, we investigated associations
between BMI and HIF3A DNA methylation in the blood and SAT from the same individuals, and whether HIF3A
gene expression in SAT and skeletal muscle biopsies showed associations with BMI and insulin resistance.
Furthermore, we aimed to investigate gender specificity and heritability of these traits.
Methods: We studied 137 first-degree relatives of type 2 diabetes (T2D) patients from 48 families, from whom we
had SAT and muscle biopsies. DNA methylation of four CpG sites in the HIF3A promoter was analyzed in the blood
and SAT by pyrosequencing, and HIF3A gene expression was analyzed in SAT and muscle by qPCR. An index of
whole-body insulin sensitivity was estimated from oral glucose tolerance tests.
Results: BMI was associated with HIF3A methylation at one CpG site in the blood, and there was a positive
association between the blood and SAT methylation levels at a different CpG site within the individuals. The SAT
methylation level did not correlate with HIF3A gene expression. Interestingly, HIF3A expression in SAT, but not in
muscle, associated negatively with BMI and whole-body insulin resistance. We found a significant effect of familiality
on HIF3A methylation levels in the blood and HIF3A expression levels in skeletal muscle.
Conclusions: Our findings are in line with the previously reported link between BMI and DNA methylation of HIF3A
in the blood. The tissue-specific results of HIF3A gene expression indicate that SAT is the more functional tissue in
which a low expression may adversely affect whole-body insulin sensitivity.
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Background
HIF3A belongs to the transcription factor family of hyp-
oxia-inducible factors (HIFs) which regulate the cellular
response to hypoxia [1]. HIFs are dimers of an α-subunit
(HIF-1α, HIF-2α, or HIF-3α) and a ß-subunit where com-
plexes of HIF-3α are thought to oppose the actions of
those formed by HIF-1α and HIF-2α [1, 2]. It has been
shown that adipose tissue-specific Hif3a knockout mice
are resistant to weight gain and have a better glucose tol-
erance and insulin sensitivity [3]. HIF-3α is highly
expressed in adipocytes and acts as an accelerator of adi-
pogenesis [4] and may also be involved in the regulation
of glucose metabolism since it is upregulated by both
insulin and 2-deoxy-D-glucose-induced glucoprivation [5].
The etiology of type 2 diabetes (T2D) consists of both
genetic and environmental factors [6]. One mechanism
whereby environmental factors can contribute to T2D is
epigenetics. Epigenetics is the study of heritable changes
in DNA that affect gene transcription irrespective of the
DNA sequence, such as methylation of DNA cytosine
residues (mainly CpG sites) [7]. Twin studies indicated
that both environmental and heritable factors affect
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epigenetic modifications [8]. Other studies have shown
that epigenetic patterns can be changed by age [9, 10]
and environmental factors such as diet and exercise
[11–14]. Methylation of gene promoter regions can lead
to silencing of gene expression whereas DNA methyla-
tion in intron-spanning regions of the gene body may re-
sult in alternative splicing [15].
A genome-wide study of DNA methylation found
positive associations between BMI and DNA methyla-
tion levels of three sites in the first intron of HIF3A
in whole blood from 479 individuals of both genders
and in subcutaneous adipose tissue from 635 women
[16]. Aside from the relation between methylation
status and BMI, these results also underline the po-
tency in whole blood DNA methylation profiling as a
marker for epigenetic changes in other human tissues
[9, 16]. For one of the investigated CpG sites, the
methylation level was inversely associated with HIF3A
gene expression in adipose tissue. Recently, other studies
replicated the findings of BMI-associated DNA methyla-
tion of HIF3A in the blood from men and women [17, 18]
and in adipose tissue where the association was only
significant in women [9].
In this study of 137 first-degree relatives of T2D
patients from 48 families, our aim was to determine
whether HIF3A methylation in the blood and SAT, and
HIF3A gene expression in SAT and skeletal muscle, are
associated with BMI and whole-body insulin sensitivity.
Furthermore, we aimed to investigate if these associa-
tions are gender specific and whether these traits are
heritable.
Methods
Study design and population
One hundred and thirty-seven Danish individuals (51
men and 86 women) from 48 different families were
recruited in 2005–2007 as part of the EUGENE2 Con-
sortium study population [19]. They were all first-degree
relatives of patients with T2D. The subjects were re-
cruited regardless of their own current glucose tolerance
status. In total, there were 48 families represented by
one member (n = 13), two (n = 12), three (n = 10), four
(n = 5), five (n = 4), six (n = 2), eight (n = 1), or ten mem-
bers (n = 1). Twenty-six individuals had T2D of which
nine received insulin treatment and were asked to dis-
continue their treatment 12 h in advance of the clinical
examination [19]. The study was approved by the Ethical
Committee of the Capital Region of Denmark (KA
05041g, 21-04-2005). All participants signed a consent
form after written and oral information.
Clinical examinations
A standard 75-g oral glucose tolerance test (OGTT) was
performed in the morning in the fasting state [19] in all
participants, and blood samples were drawn before and
30, 60, and 120 min after ingestion of the glucose load.
Plasma glucose and insulin levels were measured in all
samples. Glucose tolerance status was determined based
on WHO guidelines [20]. Whole-body insulin sensitivity
was estimated from fasting plasma glucose and insulin
levels by calculating the Matsuda insulin sensitivity
index [19, 21].
Subcutaneous adipose tissue (SAT) biopsies from the
abdomen and skeletal muscle biopsies from the vastus
lateralis muscle were taken with a Bergström needle,
snap frozen in liquid nitrogen, and stored at −80 °C until
analysis [19]. For both biopsies, Xylocain (20 mg/ml)
was used as a local anesthetic.
DNA methylation analysis
Genomic DNA was extracted from SAT using QIAamp
DNA Mini Kits (Qiagen, Hilden, Germany) and from
whole blood using blood QIAamp DNA Blood Mini Kits
(Qiagen)
The EpiTect 96 Bisulfite Kit (Qiagen) was used for
the bisulfite conversion of 400 ng genomic DNA from
whole blood and SAT. The level of methylation of
four CpG sites located between the first and second exon in
HIF3A (Fig. 1) was determined by pyrosequencing of
bisulfite-treated DNA from the blood (n = 136) and SAT
(n = 137). Primer assays were designed using the Pyro-
mark Assay Design 2.0 software (Qiagen) (forward
primer 5′-TTTTGGTTTTGGGTTTAATAAGGAA-3′,
reverse primer 5′-biotin-AAAAAAAATATTAAAAACC-
CACTCACC-3′, sequencing primer 5′-GGTGTTTTTTT
TTTTTATTTAAGGT-3′). This primer set covered two
sites previously investigated by Dick et al. (CpG site 1:
cg22891070 and CpG site 3: cg16672562) and two add-
itional sites (CpG sites 2 and 4) (Fig. 1). A third site
(cg27146050) was previously investigated by Dick et al.
[16], and to investigate this site, we used a different primer
set. However, our results on this site were not of prime
quality, possibly due to lack of primer specificity, and were
thus not included in the present study.
The PyroMark PCR kit (Qiagen) was used to amplify
the bisulfite-converted DNA according to the manufac-
turer’s protocol, and PCR amplicons were visualized
after electrophoresis through a GelRed-stained 3 %
agarose gel. The PyroMark Q96 Vacuum Workstation
(Qiagen) was used for preparation of the samples, and
pyrosequencing was performed with the Pyromark Q96
ID Instrument (Qiagen). The data was analyzed using
the PyroMark Q96 software v.2.5.8.15 and validated
manually. Samples with unreliable methylation results
were re-run (uncertainties due to baseline shift, low
signal-to-noise ratio, low peak height, and large peak
height deviation at positions that were close to the CpG
sites analyzed). All DNA methylation results from the
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re-run that did not meet the quality criteria were
excluded. The final analysis is based on 105–108 indi-
viduals in the blood and 83–84 individuals in SAT
(Additional file 1: Table S1).
Gene expression analysis
Total RNA from SAT (n = 137) was extracted with the
miRNeasy Kit (Qiagen) and converted to complementary
DNA (cDNA) by the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Grand Island,
NY, USA). Total RNA was extracted from muscle tissue
(n = 129) using TRI Reagent (Sigma-Aldrich, St. Louis,
MO, USA) and converted to cDNA using the Quanti-
Tect Reverse Transcription Kit (Qiagen) [19]. The
HIF3A gene expression in both tissues was determined
by quantitative real-time PCR on a ViiA 7 Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA)
using SYBR® Green RT-PCR Reagents Kit (Life Tech-
nologies, Grand Island, NY, USA) and primers specific
for HIF3A messenger RNA (mRNA) (NM_152794, for-
ward primer: 5′-CTTTCTGCTCTTTCCTCTCAGC-3′,
reverse primer: 5′-GCTCATTCAGGTTCAGGAGTG-3,
Tag Copenhagen, Copenhagen, Denmark). The HIF3A
mRNA quantity was normalized to the mRNA expression
of the housekeeping gene HPRT1 (forward primer: 5′-
TGACCTTGATTTATTTTGCATACC-3′, reverse primer:
5′-CGAGCAAGACGTTCAGTCCT-3′). Each sample was
run in duplicates, and we used the ΔΔCt method for quan-
tification of mRNA levels. mRNA results with Ct values
above 33 cycles or a Ct difference >0.35 on duplicates were
re-run (SAT HPRT1: 34 samples; SAT HIF3A: 0; skeletal
muscle HPRT1, HIF3A: 0), and samples still exceeding the
cut-offs after re-analysis were excluded. The final analysis
is based on 117 individuals in SAT and 120 individuals in
skeletal muscle (Additional file 1: Table S1).
Statistical analysis
The data was analyzed by a linear mixed model in R ver-
sion 3.1.0 (http://www.r-project.org) with family number
as a random factor and sex, age, BMI, and HbA1c as
fixed factors in all models. All components of the mixed
model were checked for distribution normality by evalu-
ation of histograms. Factors that did not show normal
distribution were transformed by natural logarithm. Re-
siduals from the mixed model analyses were checked for
normality by qq-plots. Furthermore, all analyses were
run separately for each sex and without inclusion of
T2D patients. The results from the mixed models are
presented as β (effect estimate) with 95 % confidence
intervals and P values. For logarithmically transformed
variables, β corresponds to percentage change. P values
≤0.05 were considered significant. Spearman’s correla-
tions (r) were used to analyze associations between
methylation levels. Using the SOLAR software (solar-
eclipse-genetics.org), the influence of familiality (i.e.,
genetic and shared environmental effects combined) on
DNA methylation and gene expression of HIF3A was es-
timated from a polygenic model as the proportion of the
additive genetic variation and shared environmental ef-
fects on the total variation (the variance component ap-
proach). In the SOLAR models, familiality of HIF3A
DNA methylation and gene expression was adjusted for
age, sex, BMI, and HbA1c levels.
Results
Clinical characteristics
The study population had a wide age span (32–83 years)
and varying levels of BMI (17.9–46.8 kg/m2) and glucose
tolerance ranging from normal to overt T2D (Table 1).
No significant differences between men and women were
found for age, BMI, or HbA1c levels. Men had higher fast-
ing circulating levels of glucose and insulin, but lower
whole-body insulin sensitivity than women (Table 1).
HIF3A DNA methylation in the blood and SAT
DNA methylation levels on CpG sites 1 and 3 were
lower compared to CpG sites 2 and 4 in the blood and
SAT. A higher level of methylation was found on all
sites in the blood compared to SAT (Fig. 2). Methylation
levels on the different CpG sites associated with each other
in both blood and SAT (blood, r = 0.39–0.69; SAT, r =
SAT: 0.46–0.71; all P < 0.001), suggesting co-methylation
Fig. 1 The four CpG sites located between exon 1 and exon 2 of HIF3A approximately 1,340 bp downstream from the transcription start site
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of the sites investigated within the HIF3A region
(Additional file 2: Figure S1 and Additional file 3:
Figure S2). Furthermore, the DNA methylation level
of CpG site 3 in the blood associated with the methy-
lation level on the same site in SAT (β = 0.35 (0.06;
0.64) P = 0.02). The methylation level on the other
three sites in the SAT and blood did not show any sta-
tistically significant associations (Additional file 4:
Table S2).
Several individuals showed a methylation level of zero
on CpG site 1 (16 individuals, 19 %) and CpG site 3 in
SAT (26 individuals, 31 %).
There were no significant differences in HIF3A DNA
methylation levels between T2D patients and non-diabetics.
HIF3A methylation levels in the blood
HIF3A DNA methylation levels at CpG sites 2 and 4 in
the blood were significantly higher in women compared
to men (Fig. 2a). At CpG site 1, we found a significant
positive association between BMI and DNA methyla-
tion (cg22891070: β = 0.263 (0.023; 0.502) P = 0.03).
The association between BMI and HIF3A methylation
at CpG site 1 persisted when T2D patients were ex-
cluded (β = 0.354 (0.111; 0.597) P = 0.004).
No significant associations between BMI and HIF3A
methylation were detected in women or men separately,
and we found no associations between whole-body insulin
sensitivity and the level of HIF3A DNA methylation in the
blood for any of the four examined methylation sites.
HIF3A methylation levels in SAT
In SAT, we found no significant effect of sex on HIF3A
DNA methylation (Fig. 2b).
Also, we found no significant association between BMI
and HIF3A methylation in SAT in all individuals or in
women or men separately for any of the four CpG sites.
However, after exclusion of T2D individuals, methylation
at CpG site 3 showed a significant association with BMI
(β = 0.304 (0.006; 0.602) P = 0.05).
HIF3A DNA methylation in SAT did not show signifi-
cant associations with the estimate of whole-body insu-
lin sensitivity.
Association between DNA methylation and gene expression
in SAT
DNA methylation levels of the four investigated CpG sites
in the HIF3A promoter did not show any significant asso-
ciation with the HIF3A gene expression level in SAT.







Age (years) 53.8 ± 12.0 53.9 ± 10.7 1.0
Weight (kg) 90.7 ± 16.8 76.3 ± 15.9 <0.0001
Height (cm) 177.2 ± 7.9 165.8 ± 6.4 <0.0001
BMI (kg/m2) 28.8 ± 3.8 27.90 ± 6.0 0.4
Glucose tolerance status
NGT (normal glucose tolerance) 26 (51 %) 61 (71 %)
IFG (impaired fasting glucose) 3 (6 %) 4 (5 %)
IGT (impaired glucose tolerance) 10 (20 %) 7 (8 %)
T2D (type 2 diabetes mellitus) 12 (24 %) 14 (16 %)
Fasting glucose (mmol/l) 6.9 ± 3.0 6.0 ± 2.1 0.02
Fasting insulin (pmol/l) 54.3 ± 35.5 46.2 ± 41.0 0.05
HbA1c (%) 5.8 ± 1.3 5.7 ± 1.0 0.6
Whole-body insulin sensitivity 6.27 ± 4.06 8.73 ± 5.29 0.007
All values are means ± SD. Fasting glucose, fasting insulin, and HbA1c values
were logarithmically transformed to obtain normal distribution prior to
analysis. P values were calculated in R 3.1.0 using a mixed linear model with
family number as a random factor and sex, age, and BMI as a fixed factor.
Glucose tolerance status: numbers (and percentage) of NGT, IFG, IGT, and
T2D individuals
Fig. 2 HIF3A promoter methylation levels of CpG sites 1 to 4 in blood (a) and SAT (b) in men and women. All values are mean ± SD. P-values for
sex difference were calculated in R with family number as a random factor. *P<0.05, adjusted for BMI and age
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HIF3A mRNA expression
HIF3A gene expression in SAT
Gene expression of HIF3A in SAT was negatively asso-
ciated with BMI in all individuals (β = −2.858 %
(−5.351; −0.30) P = 0.030) and in women alone (β =
−3.052(−5.918; −0.20) P = 0.039). This association was
not found in SAT from men alone.
Whole-body insulin sensitivity was significantly asso-
ciated with SAT HIF3A gene expression when corrected
for sex, age, BMI, and HbA1c (β = 1.813 (0.483; 3.144)
P = 0.008). The positive association between whole-
body insulin sensitivity and HIF3A gene expression
persisted after exclusion of T2D patients (β = 1.985
(0.398; 3.573) P = 0.014). When stratified for sex, the
association was significant in men (β = 2.415 (0.843;
3.987) P = 0.003), but not in women (P = 0.12).
SAT HIF3A expression levels were not significantly
different in men (0.82 ± 0.48) and women (0.74 ± 0.42)
or between T2D patients (0.70 ± 0.64) and non-diabetics
(0.79 ± 0.39).
HIF3A skeletal muscle gene expression
In skeletal muscle, the gene expression of HIF3A was
similar in women (1.07 ± 0.48) and men (0.93 ± 0.32).
HIF3A gene expression in skeletal muscle tissue was not
significantly associated with BMI. The gene expression
levels in skeletal muscle did not show any significant
association with whole-body insulin sensitivity.
Skeletal muscle HIF3A expression levels were not sig-
nificantly different in T2D patients (0.95 ± 0.39) and non-
diabetics (1.04 ± 0.44).
Finally, the gene expression level of HIF3A in skeletal
muscle was significantly associated with the gene ex-
pression level of HIF3A in SAT (β = 0.16 (0.027; 0.30)
P = 0.017).
Familiality of DNA methylation and gene expression of HIF3A
HIF3A DNA methylation levels in the blood were signifi-
cantly influenced by familiality on all sites with familial-
ity effects between 51 and 64 % (Table 2). In SAT, the
effect of familiality on HIF3A DNA methylation on CpG
sites 1 and 2 showed borderline significance (Table 2).
Gene expression of HIF3A in skeletal muscle, but not in
SAT, was significantly influenced by familiality (h2 =
43 %, P = 0.016) (Table 2).
Discussion
In line with previous studies, our current Danish study
of 137 first-degree relatives of T2D patients showed the
same positive association between BMI and HIF3A DNA
promoter methylation in the blood. This association was
also present in SAT among non-diabetic participants.
We also found an association between DNA methylation
on one site in the blood and SAT from the same individ-
uals, which is in line with the previous proposals of
whole blood DNA methylation profiling as a marker for
epigenetic changes in other human tissues [9, 16]. The
methylation level was not associated with HIF3A gene
expression in SAT. The gene expression level was nega-
tively associated with BMI and interestingly also posi-
tively with insulin sensitivity independent of BMI. This
finding suggests that SAT is a putative functional tissue
for Hif3a with the derived potential implications for
metabolic diseases.
Positive associations between BMI and HIF3A methy-
lation in the blood have been demonstrated in men and
women [16–18], whereas the association between BMI
and HIF3A methylation in SAT only has been shown in
females [9, 16]. We used a mixed-sex population, and
we did not find any sex-specific difference in the associ-
ation between BMI and DNA methylation in the blood
or SAT when men and women were studied separately.
The HIF3A DNA methylation level in the blood, how-
ever, was higher in women than in men at two of the
four CpG sites.
By including individuals from the same families, we
were able to estimate the influence of familiality (gen-
etic and shared environment effects) on DNA methyla-
tion of HIF3A. Interestingly, DNA methylation levels in
the blood showed a relatively high level of familiality
(51–64 %), and the DNA methylation pattern in SAT
showed borderline significant estimates of familiality.
Table 2 Familiality (%) of HIF3A DNA methylation and gene expression
Blood (h2 %) P SAT (h2 %) P Skeletal muscle (h2 %) P
HIF3A DNA methylation
CpG 1 (cg22891070) 56 ± 25 0.008 55 ± 37 0.08 n.a.
CpG 2 61 ± 27 0.01 44 ± 34 0.09 n.a.
CpG 3 (cg16672562) 64 ± 24 0.003 34 ± 39 0.19 n.a.
CpG 4 51 ± 26 0.02 41 ± 33 0.10 n.a.
HIF3A gene expression n.a. 12 ± 20 0.26 43 ± 21 0.02
Familiality estimates for the methylation and gene expression of HIF3A estimated using SOLAR software adjusted for age, sex, BMI, and HbA1c.
Data are means ± SD
n.a. not available
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Hence, the heritability and thereby potential genetic
influence on HIF3A DNA methylation in the blood is at
the same magnitude as that seen for obesity and T2D
[6, 22]. A recent epidemiological study suggested a
strong influence of vitamins B2 and B12 intake on the
methylation level of the HIF3A locus, providing an ex-
ample of one, potentially among several, environmental
factors influencing HIF3A DNA methylation levels [23].
The possible physiological importance of HIF3A in
SAT was highlighted by our novel findings of significant
negative associations between HIF3A expression in SAT
and both BMI and whole-body insulin resistance. The
association with BMI was predominantly driven by the
female participants whereas the association with whole-
body insulin sensitivity was significant in men, but not
in women. Taken together, our results point to a regula-
tion of SAT HIF3A expression by BMI that is most
predominant in women. On the other hand, the putative
impact of SAT HIF3A expression on glucose metabolism
seems more pronounced in men. Even though T2D and
non-diabetic individuals did not show alternating gene
expression levels, the exclusion of T2D patients did not
change the association between HIF3A mRNA expres-
sion levels in SAT and whole-body insulin sensitivity.
This suggests that the association is present already in
early stages of insulin resistance in peripheral tissues.
In line with our findings, it has previously been dem-
onstrated that a lower expression level of HIF3A in adi-
pocytes renders these cells less mature and less able to
take up fatty acids [4] which could infer insulin resist-
ance in peripheral tissues like skeletal muscle. No signifi-
cant associations between muscle HIF3A expression and
BMI or insulin sensitivity were demonstrated pointing
towards SAT as a putative functional tissue for HIF3A.
We were not able to replicate the previously reported
inverse association between a HIF3A promoter methyla-
tion and HIF3A gene expression in SAT [16]. Also, we
found no significant effect of familiality on HIF3A ex-
pression in SAT. In the muscle, we demonstrated a sig-
nificant effect of familiality on the HIF3A expression
which suggests tissue differences of genetic regulation of
HIF3A in the muscle and SAT. However, we found a
positive association between HIF3A gene expression
levels in the SAT and skeletal muscle suggesting some
degree of co-regulation.
The number of participants in our study was lower than
in the study by Dick et al. where the blood from 479 indi-
viduals of both genders and SAT from 635 women were
included and this may explain why we could only just
replicate the associations between BMI and HIF3A methy-
lation. Methylation data from SAT were only available
from a subset, and tissue from several individuals showed
no methylation. This may have lowered the statistical
power of our association analyses and familiality estimates
in the SAT compared to the blood. A major strength of
our study population is, however, the detailed phenotypic
characterization that allowed an integrative physiological
assessment, including insulin action, of the molecular
findings. Causality, however, could not be examined in the
present cross-sectional study design. Also, our study
population had a higher risk of T2D by being first-degree
relatives of T2D patients, and this may therefore not be
representative of a random population. However, this fact
may increase the relevance of the present findings for the
understanding of the mechanisms underlying the develop-
ment of T2D.
Conclusions
Our findings are in line with the previously reported posi-
tive association between BMI and HIF3A methylation in
the human blood. In the adipose tissue, however, we did
not find significant positive associations between HIF3A
methylation and BMI or whole-body insulin sensitivity.
Furthermore, we provide novel insights into the tissue-
specific regulation of HIF3A expression. Our findings
point to a role of SAT, but not muscle, HIF3A expression
for whole-body insulin sensitivity, with insulin-resistant
individuals having the lowest expression levels. Further
studies are needed to increase our understanding of the
role of HIF3A in metabolic disease.
Additional files
Additional file 1: Table S1. Total number of samples (n) with HIF3A
DNA methylation and gene expression data after quality control. (PDF 374 kb)
Additional file 2: Figure S1. Correlation between HIF3A DNA
methylation levels at CpG sites 1 to 4 in blood. (PDF 67 kb)
Additional file 3: Figure S2. Correlation between HIF3A DNA
methylation levels at CpG sites 1 to 4 in subcutaneous adipose tissue.
(PDF 126 kb)
Additional file 4: Table S2. Associations between HIF3A DNA
methylation levels in blood and subcutaneous adipose tissue. (PDF 175 kb)
Acknowledgements
M Modest and L S Koch, Steno Diabetes Center, provided technical support
for the experiments. We are especially thankful for all the study participants.
Funding
Funding for this project was received from The Danish Council for
Independent Research, The Danish Diabetes Academy supported by the
Novo Nordisk Foundation, Region Hovedstaden, Augustinus Fonden, The
Danish Strategic Research Council, P. Carl Petersens fond, Steno Diabetes
Center, Faculty of Health and Medical Sciences at Copenhagen University.
Availability of data and materials
The datasets obtained and analyzed in the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
AV, TH, and OP made substantial contributions to conception and design of
the human studies. AMM, LG, ALJ, EN, and RR-M made substantial contribu-
tions to the acquisition, analysis and interpretation of the data. APG analyzed
the familiality. AMM, LG, RR-M, and AV wrote the paper, and all authors read,
revised, and approved the final manuscript.
Main et al. Clinical Epigenetics  (2016) 8:89 Page 6 of 7
Competing interests
AMM, LG., ALJ, EN, and APG declare that they have no competing interests.
TH, OP, RR-M, and AV hold stock shares in Novo Nordisk A/S.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the Ethical Committee of the Capital Region of
Denmark (KA 05041g, 21-04-2005). All participants signed a consent form
after written and oral information.
Author details
1Department of Endocrinology, Rigshospitalet, Section 7652, Tagensvej 20,
DK-2200 Copenhagen, Denmark. 2Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark. 3Department of Clinical
Sciences, Lund University Diabetes Centre, Malmö, Sweden. 4Section of
Metabolic Genetics, The Novo Nordisk Foundation Center for Basic Metabolic
Research, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark. 5The Danish Diabetes Academy, Odense University
Hospital, Odense, Denmark.
Received: 25 July 2016 Accepted: 24 August 2016
References
1. Girgis CM, Cheng K, Scott CH, Gunton JE. Novel links between HIFs, type 2
diabetes, and metabolic syndrome. Trends Endocrinol Metab. 2012;23:372–80.
2. Heikkila M, Pasanen A, Kivirikko KI, Myllyharju J. Roles of the human hypoxia-
inducible factor (HIF)-3alpha variants in the hypoxia response. Cell Mol Life
Sci. 2011;68:3885–901.
3. Jiang C, Qu A, Matsubara T, Chanturiya T, Jou W, Gavrilova O, Shah YM,
Gonzalez FJ. Disruption of hypoxia-inducible factor 1 in adipocytes
improves insulin sensitivity and decreases adiposity in high-fat diet-fed
mice. Diabetes. 2011;60:2484–95.
4. Hatanaka M, Shimba S, Sakaue M, Kondo Y, Kagechika H, Kokame K, Miyata
T, Hara S. Hypoxia-inducible factor-3alpha functions as an accelerator of
3T3-L1 adipose differentiation. Biol Pharm Bull. 2009;32:1166–72.
5. Heidbreder M, Qadri F, Johren O, Dendorfer A, Depping R, Frohlich F,
Wagner KF, Dominiak P. Non-hypoxic induction of HIF-3alpha by 2-deoxy-
D-glucose and insulin. Biochem Biophys Res Commun. 2007;352:437–43.
6. Willemsen G, Ward KJ, Bell CG, Christensen K, Bowden J, Dalgard C, Harris
JR, Kaprio J, Lyle R, Magnusson PK, et al. The Concordance and Heritability
of Type 2 Diabetes in 34,166 Twin Pairs From International Twin Registers:
The Discordant Twin (DISCOTWIN) Consortium. Twin Res Hum Genet.
2015;18:762–71.
7. Bird A. Perceptions of epigenetics. Nature. 2007;447:396–8.
8. Ribel-Madsen R, Fraga MF, Jacobsen S, Bork-Jensen J, Lara E, Calvanese V,
Fernandez AF, Friedrichsen M, Vind BF, Hojlund K, et al. Genome-wide
analysis of DNA methylation differences in muscle and fat from
monozygotic twins discordant for type 2 diabetes. PLoS One. 2012;7:e51302.
9. Ronn T, Volkov P, Gillberg L, Kokosar M, Perfilyev A, Jacobsen AL, Jorgensen
SW, Brons C, Jansson PA, Eriksson KF, et al. Impact of age, BMI and HbA1c
levels on the genome-wide DNA methylation and mRNA expression
patterns in human adipose tissue and identification of epigenetic
biomarkers in blood. Hum Mol Genet. 2015;24(13):3792–813.
10. Johansson A, Enroth S, Gyllensten U. Continuous aging of the human DNA
methylome throughout the human lifespan. PLoS One. 2013;8:e67378.
11. Jacobsen SC, Brons C, Bork-Jensen J, Ribel-Madsen R, Yang B, Lara E, Hall E,
Calvanese V, Nilsson E, Jorgensen SW, et al. Effects of short-term high-fat
overfeeding on genome-wide DNA methylation in the skeletal muscle of
healthy young men. Diabetologia. 2012;55:3341–9.
12. Brons C, Jacobsen S, Nilsson E, Ronn T, Jensen CB, Storgaard H, Poulsen P,
Groop L, Ling C, Astrup A, Vaag A. Deoxyribonucleic acid methylation and
gene expression of PPARGC1A in human muscle is influenced by high-fat
overfeeding in a birth-weight-dependent manner. J Clin Endocrinol Metab.
2010;95:3048–56.
13. Ronn T, Volkov P, Davegardh C, Dayeh T, Hall E, Olsson AH, Nilsson E,
Tornberg A, Dekker Nitert M, Eriksson KF, et al. A six months exercise
intervention influences the genome-wide DNA methylation pattern in
human adipose tissue. PLoS Genet. 2013;9:e1003572.
14. Gillberg L, Jacobsen SC, Ronn T, Brons C, Vaag A. PPARGC1A DNA
methylation in subcutaneous adipose tissue in low birth weight subjects–
impact of 5 days of high-fat overfeeding. Metabolism. 2014;63:263–71.
15. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies
and beyond. Nat Rev Genet. 2012;13:484–92.
16. Dick KJ, Nelson CP, Tsaprouni L, Sandling JK, Aissi D, Wahl S, Meduri E,
Morange PE, Gagnon F, Grallert H, et al. DNA methylation and body-mass
index: a genome-wide analysis. Lancet. 2014;383:1990–8.
17. Wang S, Song J, Yang Y, Zhang Y, Wang H, Ma J. HIF3A DNA methylation is
associated with childhood obesity and alt. PLoS One. 2015;10:e0145944.
18. Demerath EW, Guan W, Grove ML, Aslibekyan S, Mendelson M, Zhou
YH, Hedman AK, Sandling JK, Li LA, Irvin MR, et al. Epigenome-wide
association study (EWAS) of BMI, BMI change and waist circumference
in African American adults identifies multiple replicated loci. Hum Mol
Genet. 2015;24:4464–79.
19. Gillberg L, Jacobsen S, Ribel-Madsen R, Gjesing AP, Boesgaard TW, Ling C,
Pedersen O, Hansen T, Vaag A. Does DNA methylation of PPARGC1A
influence insulin action in first degree relatives of patients with type 2
diabetes? PLoS One. 2013;8:e58384.
20. World Health Organization, 2006. Definition and diagnosis of diabetes
mellitus and intermediate. hyperglycemia. Report of a WHO/IDF
Consultation. [https://www.idf.org/webdata/docs/WHO_IDF_definition_
diagnosis_of_diabetes.pdf].
21. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin clamp.
Diabetes Care. 1999;22:1462–70.
22. Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K. The
heritability of body mass index among an international sample of
monozygotic twins reared apart. Int J Obes Relat Metab Disord. 1996;20:501–6.
23. Huang T, Zheng Y, Qi Q, Xu M, Ley SH, Li Y, Kang JH, Wiggs J, Pasquale LR,
Chan AT, et al. DNA methylation variants at hif3a locus, b-vitamin intake,
and long-term weight change: gene-diet interactions in two U.S. Cohorts.
Diabetes. 2015;64:3146–54.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Main et al. Clinical Epigenetics  (2016) 8:89 Page 7 of 7
